Anteris Secures $320m Funding, Medtronic Invests $90m in Structural Heart Company

jueves, 22 de enero de 2026, 7:22 pm ET1 min de lectura
AVR--
MDT--

Anteris Technologies has completed a US$320m capital raise, including a US$230m underwritten public offering and a US$90m strategic investment from Medtronic. The funding will support the global pivotal PARADIGM trial, manufacturing expansion, and research and development activities. The PARADIGM trial is evaluating the safety and effectiveness of DurAVR Transcatheter Heart Valve in patients with severe aortic stenosis.

Anteris Secures $320m Funding, Medtronic Invests $90m in Structural Heart Company

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios